4//SEC Filing
Mazur Leonard L 4
Accession 0001213900-24-030811
CIK 0001506251other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:05 PM ET
Size
24.2 KB
Accession
0001213900-24-030811
Insider Transaction Report
Form 4
Mazur Leonard L
DirectorChief Executive Officer
Transactions
- Award
Warrant to Purchase Common Stock
2024-04-03+1,165,048→ 1,165,048 totalExercise: $1.42Exp: 2025-04-05→ Common Stock (1,165,048 underlying) - Disposition to Issuer
Warrant to Purchase Common Stock
2024-04-03−1,165,048→ 0 totalExercise: $1.42Exp: 2024-04-05→ Common Stock (1,165,048 underlying)
Holdings
- 220,000
Stock Option (Right to Purchase Common Stock)
Exercise: $6.75Exp: 2024-09-12→ Common Stock (220,000 underlying) - 175,000
Stock Option (Right to Purchase Common Stock)
Exercise: $0.67Exp: 2029-10-08→ Common Stock (175,000 underlying) - 300,000
Stock Option (Right to Purchase Common Stock)
Exercise: $2.00Exp: 2031-07-22→ Common Stock (300,000 underlying) - 10,255,343
Common Stock
- 650,000
Stock Option (Right to Purchase Common Stock)
Exercise: $2.04Exp: 2031-10-11→ Common Stock (650,000 underlying) - 200,000
Stock Option (Right to Purchase Common Stock)
Exercise: $1.01Exp: 2030-10-06→ Common Stock (200,000 underlying) - 150,000
Stock Option (Right to Purchase Common Stock)
Exercise: $1.62Exp: 2028-09-04→ Common Stock (150,000 underlying) - 550,000
Stock Option (Right to Purchase Common Stock)
Exercise: $0.70Exp: 2033-10-10→ Common Stock (550,000 underlying) - 550,000
Stock Option (Right to Purchase Common Stock)
Exercise: $1.25Exp: 2032-10-04→ Common Stock (550,000 underlying) - 2,234,700
Warrant to Purchase Common Stock
Exercise: $0.77Exp: 2024-09-27→ Common Stock (2,234,700 underlying) - 40,000
Stock Option (Right to Purchase Common Stock)
Exercise: $3.45Exp: 2027-09-13→ Common Stock (40,000 underlying) - 3,137,255
Warrant to Purchase Common Stock
Exercise: $1.15Exp: 2024-08-14→ Common Stock (3,137,255 underlying)
Footnotes (11)
- [F1]The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately.
- [F10]The options vested in full on September 12, 2017.
- [F11]The options vested in full on September 13, 2020.
- [F2]The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F3]The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F4]The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date
- [F5]The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date
- [F6]The options vested in full on October 6, 2023.
- [F7]The options vested in full on October 8, 2022.
- [F8]The warrant is fully vested and exercisable immediately.
- [F9]The options vested in full on September 4, 2021
Documents
Issuer
Citius Pharmaceuticals, Inc.
CIK 0001506251
Entity typeother
Related Parties
1- filerCIK 0001463414
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:05 PM ET
- Size
- 24.2 KB